Reminder: jaguar health hosting april 30 investor webcast to present initial results from proof-of-concept study of crofelemer for the rare diseases microvillus inclusion disease (mvid) and short bowel syndrome with intestinal failure (sbs-if)

The webcast will review the mvid and sbs-if patient experience, the impact of crofelemer on disease progression and quality of life in mvid and sbs-if, and possible expedited regulatory pathways for crofelemer for mvid; click here to register there are currently no approved drug treatments for mvid, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management this data was presented at the annual elite ped-gi congress by dr. mohamad miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study san francisco, ca / access newswire / april 29, 2025 / jaguar health, inc. (nasdaq:jagx) (jaguar) family companies napo pharmaceuticals (napo) and napo therapeutics today issued a reminder that jaguar is hosting an investor webcast on wednesday, april 30, 2025 at 8:30 am eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (mvid) and short bowel syndrome with intestinal failure (sbs-if) that were presented by dr. mohamad miqdady on april 26, 2025 at the 11th annual elite ped-gi congress in abu dhabi in the united arab emirates. participation instructions for jaguar investor webcast when: wednesday, april 30, 2025 at 8:30 am eastern time where: online registration link for conference: click here about crofelemer crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the croton lechleri tree in the amazon rainforest.
SBS Ratings Summary
SBS Quant Ranking